Paraproteinemic neuropathies

Rebecca Traub(University of North Carolina at Chapel Hill), Chafic Karam(Amyloidosis Foundation), Adam D. Cohen(Penn Center for AIDS Research), Taha Qarni(Hospital of the University of Pennsylvania)
Muscle & Nerve
May 30, 2024
10.1002/mus.28164
Cited by 8

Related Papers

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma
|New England Journal of Medicine|2022|457
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy
|Nature Medicine|2024|254
Cevostamab Monotherapy Continues to Show Clinically Meaningful Activity and Manageable Safety in Patients with Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma (RRMM): Updated Results from an Ongoing Phase I Study
|Blood|2021|161
Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort study
|Orphanet Journal of Rare Diseases|2024|11
Hereditary Transthyretin Amyloidosis Polyneuropathy
|Seminars in Neurology|2024|4